Valproic Acid Could Help in the Fight Against COVID-19 : a case-control study
© 2022 Sociedad Española de Neurología. Published by Elsevier España, S.L.U..
OBJECTIVE: There is early evidence about Valproic acid (VPA) antiviral effect. Our aim was to investigate the incidence and severity of SARS-CoV-2 infection in VPA users as compared with the general population.
MATERIAL AND METHODS: A case-control study nested within a cohort, carried out between March 1 and December 17, 2020. Retrospectively, we identified confirmed SARS-CoV-2 infection patients exposed to VPA in our health department (defined as case). We ascertained VPA regimen (all the time (AT)(292 days) or at least 20% of the study period (notAT)(≥58 days) and if VPA levels were in therapeutic range (ATR) (50-100 mcg/mL) in the last 24 months. We calculated the cumulative incidence of SARS-CoV-2 infection and hospital admission in the cases, comparing it with the general unexposed VPA population (controls).
RESULTS: During the study period, 6183 PCR+ were detected among 281035 inhabitants, of these, 746 were hospitalized. 691 patients were on VPA notAT and 628 (90.1%) AT. The indication for VPA use was epilepsy in 54.9%. The incidence of PCR+ was 1.736 % (OR 0.785 (95%CI 0.443-1.390) and 1.910 % (OR 0.865 (95%CI 0.488-1.533), on VPA notAT and VPA AT patients, respectively vs. 2.201% in people without VPA regimen. Those patients with VPA ATR had a lower risk of PCR + (OR 0.233 (95%CI 0.057-0.951) notAT; OR 0.218 (95%CI 0.053-0.890) AT). Hospital admission incidence was lower in patient on VPA (OR was 0.543 (95% CI 0.076 to 3.871).
CONCLUSION: Patients with VPA within the therapeutic range had a reduction of SARS-Cov-2 infection incidence greater than 75%. There is a downward trend in the risk of COVID-19 admission by SARS-CoV-2 in patients on VPA therapy. These findings warrant further investigation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Neurologia (Barcelona, Spain) - (2022) vom: 14. Feb. |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
El ácido valproico podría ayudar en la lucha contra el COVID-19: un estudio de casos y controles |
|---|
| Beteiligte Personen: |
Moreno-Pérez, Oscar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 20.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.nrl.2022.01.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337170649 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337170649 | ||
| 003 | DE-627 | ||
| 005 | 20240220232035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.nrl.2022.01.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM337170649 | ||
| 035 | |a (NLM)35185237 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Moreno-Pérez, Oscar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Valproic Acid Could Help in the Fight Against COVID-19 |b a case-control study |
| 246 | 3 | 3 | |a El ácido valproico podría ayudar en la lucha contra el COVID-19: un estudio de casos y controles |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2022 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. | ||
| 520 | |a OBJECTIVE: There is early evidence about Valproic acid (VPA) antiviral effect. Our aim was to investigate the incidence and severity of SARS-CoV-2 infection in VPA users as compared with the general population | ||
| 520 | |a MATERIAL AND METHODS: A case-control study nested within a cohort, carried out between March 1 and December 17, 2020. Retrospectively, we identified confirmed SARS-CoV-2 infection patients exposed to VPA in our health department (defined as case). We ascertained VPA regimen (all the time (AT)(292 days) or at least 20% of the study period (notAT)(≥58 days) and if VPA levels were in therapeutic range (ATR) (50-100 mcg/mL) in the last 24 months. We calculated the cumulative incidence of SARS-CoV-2 infection and hospital admission in the cases, comparing it with the general unexposed VPA population (controls) | ||
| 520 | |a RESULTS: During the study period, 6183 PCR+ were detected among 281035 inhabitants, of these, 746 were hospitalized. 691 patients were on VPA notAT and 628 (90.1%) AT. The indication for VPA use was epilepsy in 54.9%. The incidence of PCR+ was 1.736 % (OR 0.785 (95%CI 0.443-1.390) and 1.910 % (OR 0.865 (95%CI 0.488-1.533), on VPA notAT and VPA AT patients, respectively vs. 2.201% in people without VPA regimen. Those patients with VPA ATR had a lower risk of PCR + (OR 0.233 (95%CI 0.057-0.951) notAT; OR 0.218 (95%CI 0.053-0.890) AT). Hospital admission incidence was lower in patient on VPA (OR was 0.543 (95% CI 0.076 to 3.871) | ||
| 520 | |a CONCLUSION: Patients with VPA within the therapeutic range had a reduction of SARS-Cov-2 infection incidence greater than 75%. There is a downward trend in the risk of COVID-19 admission by SARS-CoV-2 in patients on VPA therapy. These findings warrant further investigation | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Merino, Esperanza |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos, Jose Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz, Carmina |e verfasserin |4 aut | |
| 700 | 1 | |a Mas, Patricio |e verfasserin |4 aut | |
| 700 | 1 | |a Reus, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Martínez, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Boix, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Chico-Sánchez, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Payá, José |e verfasserin |4 aut | |
| 700 | 1 | |a Portilla, Joaquín |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurologia (Barcelona, Spain) |d 1993 |g (2022) vom: 14. Feb. |w (DE-627)NLM012988421 |x 1578-1968 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g day:14 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nrl.2022.01.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 14 |c 02 | ||